CTXR Stock Analysis: Buy, Sell, or Hold?
CTXR - Citius Pharmaceuticals Inc. Common
$0.74
-0.03 (-3.88%)
▼
5d:
-12.93%
30d:
-5.48%
90d:
-50.99%
WAIT
LOW Confidence
Last Updated: January 30, 2026
Earnings: Feb 13, 2026
10d
Get Alerted When CTXR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CTXR is down 12.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CTXR is down 12.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$2.41
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$1.50
50.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 0.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CTXR is currently trading at $0.74, which is considered oversold relative to its 30-day fair value range of $0.79 to $0.90. From a valuation perspective, the stock is trading at a discount (Forward PE: 0.2) compared to its historical average (0.4). Remarkably, the market is currently pricing in an annual earnings decline of 17.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CTXR is in a downtrend. The price is currently testing key support at $0.74. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.00 (+710.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CTXR is in a downtrend. The price is currently testing key support at $0.74. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.00 (+710.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$0.79 -
$0.90
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.9%)
- BULLISH: Trading 710.7% below Wall St target ($6.00)
- WARNING: Recommendation downgraded due to -12.9% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$0.79 -
$0.90
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$0.74
Resistance Level
$0.86
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
0.24
Wall Street Target
$6.00
(+710.7%)
Valuation Discount vs History
-17.1% cheaper
PE vs Historical
0.2 vs 0.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-17.1%
(market-implied from PE analysis)
1-Year Target
$0.67
(-10%)
2-Year Target
$0.60
(-19%)
3-Year Target
$0.54
(-27%)
3-Yr Target (if PE normalizes)
(PE: 0→0)
$0.90
(+22%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 63.2%)
$233.31
(+31425%)
Base:
(SPY PE: 0.2, Growth: 63.2%)
$2.50
(+238%)
Bear:
(PE: 0.2, Growth: 63.2%)
$2.12
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 0.2 to 0.4
Stabilization Target:
$1.24
(+67.5%)
PE Expansion Potential:
+67.5%
Last updated: February 02, 2026 7:52 AM ET
Data refreshes hourly during market hours. Next update: 8:52 AM
Data refreshes hourly during market hours. Next update: 8:52 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTXR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 60 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 57 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 60 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
